Open an account

cbdMD

YCBD · NYSE American

$0.3873+$0.0392 (+11.26%)TodayMarket closed ·
Prev close $0.3481

About YCBD

cbdMD, Inc. engages in the business of operating cannabidiol brands such as Paw cannabidiol and cbdMD botanicals. The company is headquartered in Charlotte, North Carolina. The company went IPO on 2017-11-17. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. The company operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees
42
Headquarters
Charlotte, North Carolina
Listed
Nov 17, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
cbdmd.com

YCBD key statistics

Market cap
4.94M
Price-earnings ratio
1.45
Dividend yield
—
Average volume
566.85K
Volume
75.55K
Open price
$0.3526
High today
$0.3873
Low today
$0.353
52 Week high
$2.56
52 Week low
$0.33

cbdMD (YCBD) at a glance

As of Oct 20, 2026, cbdMD (YCBD) shares are priced at $0.3873, giving the company a market cap of 4.94M and a price-to-earnings ratio of 1.45.

Today the stock has traded between $0.353 and $0.3873. The current price is 9.7% above the day's low and 0.0% below its high.

Volume so far is 75.55K shares, below the average of 566.85K shares a day.

Over the past year cbdMD has ranged from $0.33 to $2.56, and now sits 3% of the way up that range.

cbdMD met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q3 FY26 it reported -$0.09 per share against an estimate of -$0.0306.

The average analyst price target is $2.04, 426.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $2.04
Low
$2.02
Now
$0.3873
High
$2.10

YCBD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 39.2% on average.

  1. Q4 FY24: reported -$2.16 per share against an estimate of -$3.67
  2. Q1 FY25: reported -$1.76 per share against an estimate of -$3.02
  3. Q2 FY25: reported -$1.90 per share against an estimate of -$1.63
  4. Q3 FY25: reported -$0.21 per share against an estimate of -$0.0204
  5. Q4 FY25: reported -$0.17 per share against an estimate of -$0.0714
  6. Q1 FY26: reported -$0.04 per share against an estimate of -$0.0612
  7. Q2 FY26: reported -$0.08 per share against an estimate of -$0.051
  8. Q3 FY26: reported -$0.09 per share against an estimate of -$0.0306

YCBD news

  • Press releasePRNewswire

    Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation

  • Press releasePRNewswire

    cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness

  • Press releasePRNewswire

    cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

  • Press releasePRNewswire

    cbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results

  • Press releasePRNewswire

    cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releasePRNewswire

    cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

  • Press releasePRNewswire

    cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina

Similar companies

Companies in the same industry as cbdMD

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.